Spyre Therapeutics (SYRE) Cash from Operations (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Cash from Operations came in at 57372000.0 in Q1 2026, down 39.95% YoY from 95543864.48 in Q1 2025, and down 28.7% on a QoQ basis from 44578000.0 in Q4 2025.
Spyre Therapeutics (SYRE) Cash from Operations (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Cash from Operations data on file, last reported at 57372000.0 in Q1 2026.
- Quarterly Cash from Operations fell 39.95% year-over-year to 57372000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 185630000.0 (down 9.28% YoY) and the FY2025 annual result came in at 169252000.0, down 7.52% from the prior year.
- Cash from Operations eased to 57372000.0 in Q1 2026, from 44578000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 15068000.0 in Q3 2022 to a low of 62248000.0 in Q2 2024.
- A 5-year average of 33181647.06 and a median of 31036000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 1092.94% — and 2023, when it soared 32.86%.
- Tracing SYRE's Cash from Operations over 5 years: stood at 18140000.0 in 2022, then slumped by 71.09% to 31036000.0 in 2023, then decreased by 19.86% to 37199000.0 in 2024, then retreated by 19.84% to 44578000.0 in 2025, then declined by 28.7% to 57372000.0 in 2026.
- The last three Cash from Operations figures came in at 57372000.0 (Q1 2026), 44578000.0 (Q4 2025), and 37117000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | -69.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.88 Mn |
| Jun 30, 2026 | -69.88 Mn |
| Mar 31, 2026 | -57.37 Mn |
| Mar 31, 2026 | -57.37 Mn |
| Dec 31, 2025 | -44.58 Mn |
| Dec 31, 2025 | -44.58 Mn |
| Sep 30, 2025 | -37.12 Mn |
| Sep 30, 2025 | -37.12 Mn |
| Jun 30, 2025 | -46.56 Mn |
| Jun 30, 2025 | -46.56 Mn |
| Mar 31, 2025 | -40.99 Mn |
| Mar 31, 2025 | -40.99 Mn |
| Dec 31, 2024 | -37.20 Mn |
| Dec 31, 2024 | -37.20 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Sep 30, 2024 | -29.42 Mn |
| Jun 30, 2024 | -62.25 Mn |
| Jun 30, 2024 | -62.25 Mn |
| Mar 31, 2024 | -28.54 Mn |
| Mar 31, 2024 | -28.54 Mn |